Sign up

Baker Bros. Advisors LP

$20.0B assets · 84 holdings · Q2 2026 · Filed 14 AUG 2026

About Baker Bros. Advisors LP’s 13F portfolio

Baker Bros. Advisors LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Baker Bros. Advisors LP reported $20.0B across 84 US-listed positions (). Its largest position is Incyte Corporation (INCY) at 17% of the reported book, and its ten biggest holdings make up 73% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$20.0B
Assets (13F)
#319
of 8,839 by size
84
Holdings
73%
Top-10 weight
24
Buys
15
Sells
Top holdings · Q2 2026
84 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: INCY
Incyte Corporation
—
—
17%
30.8M$3.5B
2
NASDAQ: ONC
BeOne Medicines Ltd.
—
—
13%
8.8M$2.5B
3
NASDAQ: RVMD
Revolution Medicines, Inc.
—
—
11%
11.4M$2.1B
4
NASDAQ: MDGL
Madrigal Pharmaceuticals, Inc.
—
—
5.8%
2.1M$1.2B
5
NASDAQ: ACAD
ACADIA Pharmaceuticals Inc.
—
—
5.4%
42.9M$1.1B
6
NASDAQ: KYMR
Kymera Therapeutics, Inc.
—
—
5.0%
8.7M$992.7M
7
NASDAQ: INSM
Insmed Incorporated
—
—
4.7%
8.8M$937.8M
8
NASDAQ: CELC
Celcuity Inc.
—
—
4.2%
7.9M$828.2M
9
NASDAQ: KOD
Kodiak Sciences Inc.
—
—
3.9%
19.9M$776.1M
10
NASDAQ: RYTM
Rhythm Pharmaceuticals, Inc.
—
—
3.1%
5.6M$622.3M
11
NASDAQ: PRAX
Praxis Precision Medicines, Inc.
—
—
2.9%
1.8M$587.0M
12
NASDAQ: ALKS
Alkermes plc
—
—
2.6%
10.0M$524.6M
13
NASDAQ: SMMT
Summit Therapeutics Inc.
—
—
2.4%
32.8M$477.7M
14
NASDAQ: GRAL
GRAIL, Inc.
—
—
1.4%
4.0M$275.0M
15
NASDAQ: ABCL
AbCellera Biologics Inc.
—
—
1.3%
33.0M$259.1M
16
NASDAQ: IMVT
Immunovant, Inc.
—
—
1.0%
5.4M$209.4M
17
NASDAQ: IDYA
IDEAYA Biosciences, Inc.
—
—
0.9%
5.0M$186.7M
18
NASDAQ: KNSA
Kiniksa Pharmaceuticals International, plc
—
—
0.9%
2.8M$181.3M
19
NASDAQ: ROIV
Roivant Sciences Ltd.
—
—
0.8%
4.7M$166.9M
20
NASDAQ: ARWR
Arrowhead Pharmaceuticals, Inc.
—
—
0.8%
2.0M$162.4M
21
NASDAQ: IONS
Ionis Pharmaceuticals, Inc.
—
—
0.8%
2.0M$162.4M
22
NASDAQ: EWTX
Edgewise Therapeutics, Inc.
—
—
0.8%
3.7M$150.4M
23
NASDAQ: REPL
Replimune Group, Inc.
—
—
0.6%
11.0M$122.3M
24
NASDAQ: NRIX
Nurix Therapeutics, Inc.
—
—
0.6%
4.7M$113.0M
25
NASDAQ: STOK
Stoke Therapeutics, Inc.
—
—
0.5%
3.3M$109.2M

Showing 1–25 of 84 positions on this page reported in this 13F.

Sector allocation
  • Healthcare100%
Recent activity · vs 2026-03-31
Bought24
  • AddedINCYIncyte Corporation+0.1%$3.5B
  • AddedONCBeOne Medicines Ltd.+0.0%$2.5B
  • AddedRVMDRevolution Medicines, Inc.+19.8%$2.1B
  • AddedMDGLMadrigal Pharmaceuticals, Inc.+0.1%$1.2B
  • AddedACADACADIA Pharmaceuticals Inc.+0.0%$1.1B
  • AddedINSMInsmed Incorporated+18.5%$937.8M
  • AddedABCLAbCellera Biologics Inc.+9.0%$259.1M
  • AddedIDYAIDEAYA Biosciences, Inc.+26.9%$186.7M
  • AddedKNSAKiniksa Pharmaceuticals International, plc+0.3%$181.3M
  • AddedDNLIDenali Therapeutics Inc.+0.1%$96.0M
Sold15
  • ReducedSMMTSummit Therapeutics Inc.−9.9%$477.7M
  • ReducedIMVTImmunovant, Inc.−0.4%$209.4M
  • ReducedROIVRoivant Sciences Ltd.−3.1%$166.9M
  • ReducedEWTXEdgewise Therapeutics, Inc.−43.7%$150.4M
  • ReducedIMTXImmatics N.V.−12.9%$96.3M
  • ReducedJBIOJade Biosciences, Inc.−25.0%$27.3M
  • ReducedCERSCerus Corporation−36.1%$18.7M
  • SoldPHVSPharvaris N.V.−100%—
  • SoldARGXargenx SE−100%—
  • SoldCTNMContineum Therapeutics, Inc.−100%—
5%+ Beneficial Ownership Stakes · 9 activist (13D) · 14 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
KOD
Kodiak Sciences Inc.
13D35.0% · 2 classes22.0MFiled 30 SEP 2026
2
PRLD
Prelude Therapeutics Inc
13D23.5% · 2 classes10.3MFiled 13 JUN 2025
3
SERA
Sera Prognostics, Inc.
13D16.1%5.5MFiled 14 FEB 2025
4
INCY
Incyte Corp
13D15.7% · 2 classes31.2MFiled 10 FEB 2026
5
REPL
Replimune Group, Inc.
13D14.3% · 2 classes11.0MFiled 07 MAR 2025
6
KYMR
Kymera Therapeutics, Inc.
13D10.9%8.7MFiled 11 DEC 2025
7
ABCL
AbCellera Biologics Inc.
13G10.8%33.0MFiled 07 MAY 2026
8
DBVT
DBV Technologies S.A.
13D10.0%25.6MFiled 14 JAN 2026
9
GLUE
Monte Rosa Therapeutics, Inc.
13G10.0% · 2 classes8.9MFiled 15 MAY 2026
10
CELC
Celcuity Inc.
13G10.0% · 2 classes4.9MFiled 16 JUL 2026
11
KALA
KALA BIO, Inc.
13G10.0%2.9MFiled 17 FEB 2026
12
IMTX
Immatics N.V.
13G9.9%12.1MFiled 14 NOV 2025
13
GRAL
GRAIL, Inc.
13G9.8% · 2 classes4.0MFiled 15 MAY 2026
14
RYTM
Rhythm Pharmaceuticals, Inc.
13G8.9%5.6MFiled 15 MAY 2025
15
BEIGF
BeOne Medicines Ltd.
13D7.8%115.9MFiled 16 SEP 2026
16
NRIX
Nurix Therapeutics, Inc.
13G7.2%7.5MFiled 17 FEB 2026
17
KNSA
Kiniksa Pharmaceuticals International, plc
13D7.0%3.3MFiled 26 MAY 2026
18
NGNE
Neurogene Inc.
13G7.0%992KFiled 14 AUG 2025
19
EWTX
Edgewise Therapeutics, Inc.
13G6.9%7.3MFiled 14 AUG 2025
20
PRAX
Praxis Precision Medicines, Inc.
13G6.3%1.8MFiled 15 MAY 2026
21
ALKS
Alkermes plc.
13G6.1%10.0MFiled 17 FEB 2026
22
STOK
Stoke Therapeutics, Inc.
13G5.8%3.3MFiled 17 FEB 2026
23
IDYA
IDEAYA Biosciences, Inc.
13G5.2%5.0MFiled 14 AUG 2026

Showing all 23 disclosed stakes. 6 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Baker Bros. Advisors LP’s 13F portfolio

Baker Bros. Advisors LP’s $20.0B 13F book is spread across 84 reported positions and is highly concentrated — its ten largest positions alone are 73% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are INCY, ONC, RVMD, MDGL and ACAD, led by Incyte Corporation (INCY) at 17% of the portfolio. The heaviest sector exposure is Healthcare (100%).

What Baker Bros. Advisors LP changed last quarter

Between 2026-03-31 and Q2 2026, Baker Bros. Advisors LP was a net buyer: it opened 8 new positions and added to 16 more, while trimming 7 and closing 8 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Incyte Corporation (INCY), and its biggest reduction was Summit Therapeutics Inc. (SMMT).

What a 13F does and doesn’t reveal

A 13F captures only Baker Bros. Advisors LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Baker Bros. Advisors LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Baker Bros. Advisors LP's profile on this page is built directly from those filings.

How current is the 13F data on Baker Bros. Advisors LP's page?

It reflects Baker Bros. Advisors LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Baker Bros. Advisors LP files its next quarterly report, this page refreshes automatically.

Can I see Baker Bros. Advisors LP's complete list of holdings?

This page highlights Baker Bros. Advisors LP's largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Baker Bros. Advisors LP's filings.

Does a 13F show everything Baker Bros. Advisors LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Baker Bros. Advisors LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Baker Bros. Advisors LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.